Table 2

Clinician group funding recommendation and supporting evidence

Clinician group recommendation (n=48)
Fund (n=46)Do not fund (n=2)
CADTH decision
 Positive29 (63)0 (0)
 Negative12 (26)2 (100)
Submission with conflicts
 Yes44 (96)1 (50)
 No2 (4)1 (50)
Submissions with conflicts with manufacturer
 Yes34 (74)1 (50)
 No12 (26)1 (50)
ESMO-MCBS score
 Substantial benefit23 (50)2 (100)
 No substantial benefit23 (50)0 (0)
RCT
 Yes34 (74)2 (100)
 No12 (26)0 (0)
Phase
 13 (7)0 (0)
 210 (22)0 (0)
 333 (72)2 (100)
Blinded studies
 Yes20 (43)2 (100)
 No14 (30)0 (0)
 NR12 (26)0 (0)
OS
 Improved18 (39)0 (0)
 Not improved12 (26)1 (50)
 NA16 (35)1 (50)
PFS data
 Improved25 (54)0 (0)
 Not improved5 (11)0 (0)
 NA16 (35)2 (100)
HRQoL
 Improved5 (11)0 (0)
 No change32 (70)2 (100)
 Worsen1 (2)0 (0)
 NA5 (11)0 (0)
Price (per 28 cycle)
 Under $50005 (11)0 (0)
 $5000–$999927 (59)1 (50)
 Over $10 00014 (30)1 (50)
  • CADTH, Canadian Agency for Drugs and Technology in Health; ESMO-MCBS, European Society for Medical Oncology Magnitude of Clinical Benefit Scale; HRQoL, health-related quality of life; NA, not available; NR, not reported; OS, overall survival; PFS, progression-free survival; RCT, randomised controlled trial.